Correction to: Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial

被引：0
|
作者：
Bee Kim Tan
Siew Siang Chua
Li-Chia Chen
Kian Meng Chang
Sharmini Balashanker
Ping Chong Bee
机构：
[1] Jalan Universiti,Department of Medicine, Faculty of Medicine, University of Malaya
[2] Taylor’s University,School of Pharmacy, Faculty of Health and Medical Sciences
[3] University of Manchester,Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health
[4] Manchester Academic Health Science Centre,Department of Hematology
[5] Ampang Hospital,School of Pharmacy
[6] Ministry of Health Malaysia,undefined
[7] University of Nottingham Malaysia Campus,undefined
来源：
Supportive Care in Cancer | 2020年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Revised Funding Information.
引用
收藏
页码：3249 / 3249
相关论文
共 50 条
  • [21] Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors
    Chopade, Pradnya
    Akard, Luke P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (11): : 710 - 723
  • [22] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Kristin M. Phillips
    Javier Pinilla-Ibarz
    Eduardo Sotomayor
    Morgan R. Lee
    Heather S. L. Jim
    Brent J. Small
    Lubomir Sokol
    Jeffrey Lancet
    Sara Tinsley
    Kendra Sweet
    Rami Komrokji
    Paul B. Jacobsen
    Supportive Care in Cancer, 2013, 21 : 1097 - 1103
  • [23] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Phillips, Kristin M.
    Pinilla-Ibarz, Javier
    Sotomayor, Eduardo
    Lee, Morgan R.
    Jim, Heather S. L.
    Small, Brent J.
    Sokol, Lubomir
    Lancet, Jeffrey
    Tinsley, Sara
    Sweet, Kendra
    Komrokji, Rami
    Jacobsen, Paul B.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (04) : 1097 - 1103
  • [24] Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study
    Kekale, Meri
    Soderlund, Tim
    Koskenvesa, Perttu
    Talvensaari, Kimmo
    Airaksinen, Marja
    JOURNAL OF ADVANCED NURSING, 2016, 72 (09) : 2196 - 2206
  • [25] EFFICACY AND SAFETY OF BOSUTINIB IN PATIENTS WITH RESISTANT CHRONIC MYELOID LEUKAEMIA OR INTOLERANT TO ATLEAST 3 INHIBITORS OF PRIOR TYROSINE KINASE
    Valentin, Garcia-Gutierrez
    Dragana, Milojkovic
    Luis Felipe, Casado
    Simone, Claudiani
    Antonio, Jimenez-Velasco
    Maria Luisa, Marten-Mateos
    Concepcion, Boque
    Alejandra, Martinez-Trillo
    Isabel, Mata
    Payer Angel, Ramirez
    Alberto, Alvarez-Larran
    Elena, Amutio
    Garcia Abelardo, Barez
    Guiomar, Bautista
    Barela Sabela, Bobillo
    Ruiz Beatriz, Cuevas
    Pilar, Giraldo
    Jose Manuel, Puerta
    Maria Jose, Ramirez
    Gerosa Silvana, Saavedra
    Sandra, Valencia
    Rivas Fernando, Ortega
    Mas Ana, Rossel
    Fabio, Ruiz
    Juan Luis, Steegmann
    HAEMATOLOGICA, 2016, 101 : 79 - 80
  • [26] Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
    Nishiyama-Fujita, Yuriko
    Nakazato, Tomonori
    Iriyama, Noriyoshi
    Tokuhira, Michihide
    Ishikawa, Maho
    Sato, Eriko
    Takaku, Tomoiku
    Sugimoto, Keiji
    Fujita, Hiroyuki
    Fujioka, Isao
    Tsuchiya, Shun
    Kimura, Yuta
    Iwanaga, Eisaku
    Komatsu, Norio
    Asou, Norio
    Kizaki, Masahiro
    Hatta, Yoshihiro
    Kawaguchi, Tatsuya
    ANNALS OF MEDICINE, 2022, 54 (01) : 1244 - 1254
  • [27] Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
    Kekale, Meri
    Talvensaari, Kimmo
    Koskenvesa, Perttu
    Porkka, Kimmo
    Airaksinen, Marja
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1619 - 1627
  • [28] Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
    Richard E. Clark
    Current Hematologic Malignancy Reports, 2019, 14 : 507 - 514
  • [29] Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
    Clark, Richard E.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (06) : 507 - 514
  • [30] Cutaneous adverse reactions to tyrosine kinase inhibitors in a cohort of patients treated for chronic myeloid leukaemia
    Sears, A.
    Orrin, E.
    Salisbury, J.
    Mufti, G.
    De Lavallade, H.
    Basu, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 52 - 52
12345